| pubmed-article:6101148 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6101148 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:6101148 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:6101148 | lifeskim:mentions | umls-concept:C0302908 | lld:lifeskim |
| pubmed-article:6101148 | lifeskim:mentions | umls-concept:C0033497 | lld:lifeskim |
| pubmed-article:6101148 | lifeskim:mentions | umls-concept:C0184661 | lld:lifeskim |
| pubmed-article:6101148 | lifeskim:mentions | umls-concept:C0242485 | lld:lifeskim |
| pubmed-article:6101148 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:6101148 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:6101148 | lifeskim:mentions | umls-concept:C0439858 | lld:lifeskim |
| pubmed-article:6101148 | lifeskim:mentions | umls-concept:C0048395 | lld:lifeskim |
| pubmed-article:6101148 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:6101148 | pubmed:dateCreated | 1993-4-21 | lld:pubmed |
| pubmed-article:6101148 | pubmed:abstractText | An assay is described for the simultaneous determination of propranolol and its active metabolite, 4-hydroxypropranolol, in human plasma. Both compounds were separated from an ethereal extract by high-performance liquid chromatography employing a C18 bonded-phase column. Detection of the effluent was by fluorescence. Suitable fluorescent spectrometers and wavelength settings that allow optimum detection of both compounds have been described. The limit of sensitivity was 2 ng/ml for both propranolol and 4-hydroxypropranolol. Mean peak plasma levels of propranolol and 4-hydroxypropranolol in six patients receiving a single dose of a slow-release 160-mg formulation of propranolol were 28 and 6 ng/ml, respectively. These levels were about one-tenth the level obtained following a single conventionally prepared dose of propranolol (160 mg). Peak levels were delayed and plasma levels of propranolol persisted for a longer period with the slow-release formulation. Area under the curve estimates suggested that the bioavailability of the slow-release formulation following single-dose administration was about one-third that of the conventional preparation. | lld:pubmed |
| pubmed-article:6101148 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6101148 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6101148 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6101148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6101148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6101148 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6101148 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6101148 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:6101148 | pubmed:issn | 0022-3549 | lld:pubmed |
| pubmed-article:6101148 | pubmed:author | pubmed-author:LouisW JWJ | lld:pubmed |
| pubmed-article:6101148 | pubmed:author | pubmed-author:DrummerO HOH | lld:pubmed |
| pubmed-article:6101148 | pubmed:author | pubmed-author:McNeilJJ | lld:pubmed |
| pubmed-article:6101148 | pubmed:author | pubmed-author:PritchardEE | lld:pubmed |
| pubmed-article:6101148 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6101148 | pubmed:volume | 70 | lld:pubmed |
| pubmed-article:6101148 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6101148 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6101148 | pubmed:pagination | 1030-2 | lld:pubmed |
| pubmed-article:6101148 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6101148 | pubmed:meshHeading | pubmed-meshheading:6101148-... | lld:pubmed |
| pubmed-article:6101148 | pubmed:meshHeading | pubmed-meshheading:6101148-... | lld:pubmed |
| pubmed-article:6101148 | pubmed:meshHeading | pubmed-meshheading:6101148-... | lld:pubmed |
| pubmed-article:6101148 | pubmed:meshHeading | pubmed-meshheading:6101148-... | lld:pubmed |
| pubmed-article:6101148 | pubmed:meshHeading | pubmed-meshheading:6101148-... | lld:pubmed |
| pubmed-article:6101148 | pubmed:meshHeading | pubmed-meshheading:6101148-... | lld:pubmed |
| pubmed-article:6101148 | pubmed:meshHeading | pubmed-meshheading:6101148-... | lld:pubmed |
| pubmed-article:6101148 | pubmed:year | 1981 | lld:pubmed |
| pubmed-article:6101148 | pubmed:articleTitle | Combined high-performance liquid chromatographic procedure for measuring 4-hydroxypropranolol and propranolol in plasma: pharmacokinetic measurements following conventional and slow-release propranolol administration. | lld:pubmed |
| pubmed-article:6101148 | pubmed:affiliation | Clinical Pharmacology & Therapeutics Unit, Austin Hospital, University of Melbourne, Heidelberg, Victoria, Australia. | lld:pubmed |
| pubmed-article:6101148 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6101148 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:6101148 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6101148 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6101148 | lld:pubmed |
